A. Omuro and L. M. Deangelis, Glioblastoma and Other Malignant Gliomas: A Clinical Review, JAMA, vol.310, issue.17, pp.1842-50, 2013.

D. N. Louis, A. Perry, G. Reifenberger, . Deimling-a-von, D. Figarella-branger et al., The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary, Acta Neuropathol (Berl), vol.131, issue.6, pp.803-823, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01479018

R. Stupp, M. E. Hegi, W. P. Mason, M. J. Van-den-bent, M. Taphoorn et al., Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial, Lancet Oncol, vol.10, issue.5, pp.459-66, 2009.

R. Stupp, W. P. Mason, M. J. Van-den-bent, M. Weller, B. Fisher et al., Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma, N Engl J Med, vol.352, issue.10, pp.987-96, 2005.

J. H. Chang, C. Kim, B. S. Choi, Y. J. Kim, J. S. Kim et al., Pseudoprogression and Pseudoresponse in the Management of High-Grade Glioma : Optimal Decision Timing According to the Response Assessment of the Neuro-Oncology Working Group, J Korean Neurosurg Soc, vol.55, issue.1, pp.5-11, 2014.

J. Fink, D. Born, and M. C. Chamberlain, Pseudoprogression: Relevance With Respect to Treatment of High-Grade Gliomas, Curr Treat Options Oncol, vol.12, issue.3, p.240, 2011.

B. Nabors and J. Laterra, Neuro-Oncology: Current Concepts and Emerging Therapeutics, Neurotherapeutics, vol.14, issue.2, pp.253-258, 2017.
DOI : 10.1007/s13311-017-0529-8

URL : https://link.springer.com/content/pdf/10.1007%2Fs13311-017-0529-8.pdf

P. D. Chang, D. S. Chow, P. H. Yang, C. G. Filippi, and A. Lignelli, Predicting Glioblastoma Recurrence by Early Changes in the Apparent Diffusion Coefficient Value and Signal Intensity on FLAIR Images, Am J Roentgenol, vol.208, issue.1, pp.57-65, 2016.

I. D. Crain, P. S. Elias, K. Chapple, A. C. Scheck, J. P. Karis et al., Improving the utility of 1H-MRS for the differentiation of glioma recurrence from radiation necrosis, J Neurooncol, vol.133, issue.1, pp.97-105, 2017.

B. Wan, S. Wang, M. Tu, B. Wu, P. Han et al., The diagnostic performance of perfusion MRI for differentiating glioma recurrence from pseudoprogression, Medicine

N. Galldiks and K. Langen, Amino acid PET in neuro-oncology: applications in the clinic, Expert Rev Anticancer Ther, vol.17, issue.5, pp.395-402, 2017.

N. Galldiks, I. Law, W. B. Pope, J. Arbizu, and K. Langen, The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy, NeuroImage Clin, vol.13, pp.386-94, 2017.

F. Walter, T. Cloughesy, M. A. Walter, A. Lai, P. Nghiemphu et al., Impact of 3,4Dihydroxy-6-18F-Fluoro-l-Phenylalanine PET/CT on Managing Patients with Brain Tumors: The Referring Physician's Perspective, J Nucl Med, vol.53, issue.3, pp.393-401, 2012.

J. Darcourt, L. Mondot, F. Burel-vandenbos, P. Bondiau, F. Almairac et al., Clinical impact of 18F-FDOPA PET in the differential diagnosis between recurrence and radiation necrosis in brain tumors, J Nucl Med, vol.58, pp.75-75, 2017.

K. J. Lizarraga, M. Allen-auerbach, J. Czernin, A. Desalles, W. H. Yong et al., 18FFDOPA PET for Differentiating Recurrent or Progressive Brain Metastatic Tumors from Late or Delayed Radiation Injury After Radiation Treatment, J Nucl Med, vol.55, issue.1, pp.30-36, 2014.

K. Herrmann, J. Czernin, T. Cloughesy, A. Lai, K. L. Pomykala et al., Comparison of visual and semiquantitative analysis of 18F-FDOPA-PET/CT for recurrence detection in glioblastoma patients, Neuro-Oncol, vol.16, issue.4, pp.603-612, 2014.

W. Chen, D. Silverman, S. Delaloye, J. Czernin, N. Kamdar et al., 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy, J Nucl Med Off Publ Soc Nucl Med, vol.47, issue.6, pp.904-915, 2006.

B. Dadone-montaudié, D. Ambrosetti, M. Dufour, J. Darcourt, F. Almairac et al., 18F] FDOPA standardized uptake values of brain tumors are not exclusively dependent on LAT1 expression, PloS One, vol.12, issue.9, p.184625, 2017.

R. S. Youland, G. J. Kitange, T. E. Peterson, D. H. Pafundi, J. A. Ramiscal et al., The role of LAT1 in 18F-DOPA uptake in malignant gliomas, J Neurooncol, vol.111, issue.1, pp.11-19, 2013.

A. Chiaravalloti, A. Fiorentini, V. Villani, C. Carapella, A. Pace et al., Factors affecting 18F FDOPA standardized uptake value in patients with primary brain tumors after treatment, Nucl Med Biol, vol.42, issue.4, pp.355-364, 2015.

B. J. Fueger, J. Czernin, T. Cloughesy, D. H. Silverman, C. L. Geist et al., Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas, J Nucl Med Off Publ Soc Nucl Med, vol.51, issue.10, pp.1532-1540, 2010.

, Correlation of SUV-Derived Indices With Tumoral, Clinical Nuclear Medicine

F. Tumors, Clinical Nuclear Medicine

A. Verger, P. Metellus, Q. Sala, C. Colin, E. Bialecki et al., IDH mutation is paradoxically associated with higher 18F-FDOPA PET uptake in diffuse grade II and grade III gliomas, Eur J Nucl Med Mol Imaging, vol.44, issue.8, pp.1306-1317, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01735109

Q. Sala, P. Metellus, O. Chinot, L. Boyer, E. Bialecki et al., Évaluation préopératoire comparative de 43 gliomes de grade II et III par TEP au 18F-FDG et à la 18F-DOPA : corrélation aux données histologiques et moléculaires. Médecine Nucl, vol.40, pp.285-96, 2016.

E. Bosnyák, S. K. Michelhaugh, N. V. Klinger, D. O. Kamson, G. R. Barger et al., Prognostic Molecular and Imaging Biomarkers in Primary Glioblastoma, Clin Nucl Med, vol.42, issue.5, pp.341-348, 2017.

F. Liu and P. S. Mischel, Targeting epidermal growth factor receptor co-dependent signaling pathways in glioblastoma, Wiley Interdiscip Rev Syst Biol Med

K. J. Hatanpaa, S. Burma, D. Zhao, and A. A. Habib, Epidermal Growth Factor Receptor in Glioma: Signal Transduction, Neuropathology, Imaging, and Radioresistance, Neoplasia N Y N, vol.12, issue.9, pp.675-84, 2010.

C. J. Ledezma, W. Chen, V. Sai, B. Freitas, T. Cloughesy et al., 18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: Initial experience, Eur J Radiol, vol.71, issue.2, pp.242-250, 2009.

S. Karunanithi, P. Sharma, A. Kumar, B. C. Khangembam, G. P. Bandopadhyaya et al., 18F-FDOPA PET/CT for detection of recurrence in patients with glioma: prospective comparison with 18F-FDG PET/CT, Eur J Nucl Med Mol Imaging, vol.40, issue.7, pp.1025-1060, 2013.

F. Walter, T. Cloughesy, M. A. Walter, A. Lai, P. Nghiemphu et al., Impact of 3,4Dihydroxy-6-18F-Fluoro-l-Phenylalanine PET/CT on Managing Patients with Brain Tumors: The Referring Physician's Perspective, J Nucl Med, vol.53, issue.3, pp.393-401, 2012.

T. Kato, J. Shinoda, N. Nakayama, K. Miwa, A. Okumura et al., Metabolic Assessment of Gliomas Using 11C-Methionine, [18F] Fluorodeoxyglucose, and 11C-Choline PositronEmission Tomography, Am J Neuroradiol, vol.29, issue.6, pp.1176-82, 2008.

N. Tsuyuguchi, Y. Terakawa, T. Uda, K. Nakajo, and Y. Kanemura, Diagnosis of Brain Tumors Using Amino Acid Transport PET Imaging with 18F-fluciclovine: A Comparative Study with L-methyl11C-methionine PET Imaging, Asia Ocean J Nucl Med Biol, vol.5, issue.2, pp.85-94, 2017.

J. Felsberg, B. Hentschel, K. Kaulich, D. Gramatzki, A. Zacher et al., Prognostic role of Epidermal growth factor receptor variant III (EGFRvIII) positivity in EGFR-amplified primary and recurrent glioblastomas, Clin Cancer Res, 2017.

R. Verhaak, K. A. Hoadley, E. Purdom, V. Wang, Y. Qi et al., An integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1. Cancer Cell, vol.17, p.98, 2010.

I. Nakano, Stem cell signature in glioblastoma: therapeutic development for a moving target, J Neurosurg, vol.122, issue.2, pp.324-354, 2014.

P. Mao, K. Joshi, J. Li, S. Kim, P. Li et al., Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3, Proc Natl Acad Sci, vol.110, issue.21, pp.8644-8653, 2013.

S. Yip, J. Kim, T. P. Coroller, C. Parmar, E. R. Velazquez et al., Associations Between Somatic Mutations and Metabolic Imaging Phenotypes in Non-Small Cell Lung Cancer. J Nucl Med Off Publ Soc Nucl Med, vol.58, pp.569-76, 2017.

A. Liu, A. Han, H. Zhu, L. Ma, Y. Huang et al., The role of metabolic tumor volume (MTV) measured by [18F] FDG PET/CT in predicting EGFR gene mutation status in non-small cell lung cancer, Oncotarget, vol.8, issue.20, pp.33736-33780, 2017.

K. Takamochi, K. Mogushi, H. Kawaji, K. Imashimizu, M. Fukui et al., Correlation of EGFR or KRAS mutation status with 18F-FDG uptake on PET-CT scan in lung adenocarcinoma, PLOS ONE, vol.12, issue.4, p.175622, 2017.

J. Biau, P. Dalloz, X. Durando, M. Hager, Z. G. Ouédraogo et al., Glioblastome du sujet âgé : état de l'art. Bull Cancer (Paris), vol.102, pp.277-86, 2015.

J. Chen, H. Xu, Y. Yao, and Z. Qin, Prognostic value of epidermal growth factor receptor amplification and EGFRvIII in glioblastoma: meta-analysis, Acta Neurol Scand, vol.132, issue.5, pp.310-332, 2015.

N. Montano, T. Cenci, M. Martini, D. 'alessandris, Q. G. Pelacchi et al., Expression of EGFRvIII in Glioblastoma: Prognostic Significance Revisited, Neoplasia N Y N, vol.13, issue.12, pp.1113-1134, 2011.

M. Weller, M. Van-den-bent, K. Hopkins, J. C. Tonn, R. Stupp et al., EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma, Lancet Oncol, vol.15, issue.9, pp.395-403, 2014.

J. Hobbs, M. N. Nikiforova, D. W. Fardo, S. Bortoluzzi, K. Cieply et al., Paradoxical relationship between degree of EGFR amplification and outcome in glioblastomas, Am J Surg Pathol, vol.36, issue.8, pp.1186-93, 2012.

B. Suchorska, N. L. Jansen, J. Linn, H. Kretzschmar, H. Janssen et al., Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM, Neurology, vol.84, issue.7, pp.710-719, 2015.

T. Jung, J. Min, H. Bom, J. S. Kim, I. Lim et al., Prognostic value of posttreatment metabolic tumor volume from 11C-methionine PET/CT in recurrent malignant glioma, Neurosurg Rev, vol.40, issue.2, pp.223-232, 2017.

, Annexe 2. Echelle visuelle selon Lizarraga pour différencier récidive et radionécrose

, Annexe 3. Voies de signalisation affectées par les amplifications géniques dans les GB

, Annexe 5. Sous-types moléculaires de GB selon la classification de Verhaak, 2010.